Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELI-002 7P in KRAS/NRAS Mutated Solid Tumors
NCT05726864Phase 2Active, not recruiting
- Sponsor
- Elicio Therapeutics
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ELI-002 in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and solid tumor (5 arms), sponsored by Elicio Therapeutics. Primary endpoints: Safety of ELI-002 7P at 28 days and Disease Free Survival at Week 150. Started Apr 2023; status: active, not recruiting.
02
Drugs
ELI-002
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT05726864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726864.